Rate My Professor Adam Doyle

Doyle serves as principal investigator for clinical trials in hepatocellular carcinoma at Royal Perth Hospital and as clinical lead for the prison telehealth hepatitis C treatment program. His research focuses on liver diseases, including viral hepatitis, fatty liver disease, hepatocellular carcinoma, autoimmune liver disease, and liver transplantation. He has published multiple articles in peer-reviewed journals, with his work cited over 1,200 times according to Google Scholar. Key publications include "Global multi-stakeholder endorsement of the MAFLD definition" in The Lancet Gastroenterology & Hepatology (2022), "Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients" in Journal of Hepatology (2019), "Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation" in Journal of Hepatology (2019), "Donor BMI> 30 is not a contraindication for live liver donation" in American Journal of Transplantation (2017), "The Impact of Preexisting and Post-transplant Diabetes Mellitus on Outcomes Following Liver Transplantation" in Transplantation (2019), "Treatment with Optifast reduces hepatic steatosis and increases candidacy rates for living donor liver transplantation" in Liver Transplantation (2016), "Autoimmune hepatitis during infliximab therapy for Crohn's disease" in Journal of Crohn's and Colitis (2011), and "Use of telehealth to increase treatment access for prisoners with chronic hepatitis C infection" in Internal Medicine Journal (2021). Recent contributions encompass "Histological Findings of Hypervitaminosis A Liver Disease" in Gastro Hep Advances (2024) and studies on rural patient outcomes in hepatocellular carcinoma (Internal Medicine Journal, 2025).